Get started
Author

Ece Erbağcı

Observed names: Ece ERBAĞCI, Ece Erbagci, Erbağcı, Ece
Institution: Usak University
ORCID: 0000-0002-2887-0492
Observed ORCID: 0000-0002-2887-0492
OpenAlex ID: A5027430846
Scabies Affects Quality of Life in Correlation with Depression and Anxiety
2023 · Sema Koç Yıldırım, Neslihan Demirel Öğüt, et al. · Dermatology Practical & Conceptual · 23
PDF
Are IL-17 inhibitors superior to IL-23 inhibitors in reducing systemic inflammation in moderate-to-severe plaque psoriasis? A retrospective cohort study
2025 · Neslihan Demirel Öğüt, Mehmet Anıl Ayanoğlu, et al. · Archives of Dermatological Research · 22
Evaluation of patients with telogen effluvium during the pandemic: May the monocytes be responsible for post COVID‐19 telogen effluvium?
2022 · Sema Koç Yıldırım, Ece Erbağcı, et al. · Journal of Cosmetic Dermatology · 16
PDF
Ixekizumab treatment in patients with moderate‐to‐severe plaque psoriasis in a real‐world clinical setting
2022 · Neslihan Demirel Öğüt, Sema Koç Yıldırım, et al. · Journal of Cosmetic Dermatology · 11
Dermatologic comorbidities of the patients with severe COVID ‐19: A case‐control study
2021 · Ömer Kutlu, Neslihan Demirel Öğüt, et al. · Dermatologic Therapy · 11
PDF
Oral isotretinoin treatment in patients with acne vulgaris during the COVID‐19 pandemic: A retrospective cohort study in a tertiary care hospital
2021 · Neslihan Demirel Öğüt, Ömer Kutlu, et al. · Journal of Cosmetic Dermatology · 8
PDF
Secukinumab Treatment in Patients With Hidradenitis Suppurativa in Real-World Clinical Settings: A Multicenter Study
2025 · Ece Erbağcı, Özge Sevil Karstarlı Bakay, et al. · Dermatology Practical & Conceptual · 7
PDF
Evaluation of serial QuantiFERON ‐ TB Gold in tube test results and tuberculosis infection status in patients with psoriasis receiving anti‐ IL ‐17 treatment (secukinumab and ixekizumab): Real‐world data from a tuberculosis‐endemic country
2024 · Ece Erbağcı, Sema Koç Yıldırım, et al. · Australasian Journal of Dermatology · 7
Retrospective evaluation of patients with chronic spontaneous urticaria using omalizumab during the COVID‐19 pandemic
2022 · Sema Koç Yıldırım, Neslihan Demirel Öğüt, et al. · Journal of Cosmetic Dermatology · 7
PDF
Predictors of relapse after omalizumab withdrawal in chronic spontaneous urticaria: Role of baseline autoimmunity and hematologic indices: CSU Relapse After Omalizumab Withdrawal
2026 · Sema Koc Yildirim, Ece Erbagci, et al. · Allergy and Asthma Proceedings · 5
Omalizumab treatment in combination with any other biologics: Is it really a safe duo?
2023 · Sema Koç Yıldırım, Ece Erbağcı, et al. · Australasian Journal of Dermatology · 5
Is dupilumab effective in adult‐onset atopic dermatitis: Real‐life experience of 16 patients
2022 · Ece Erbağcı, Neslihan Demirel Öğüt, et al. · Journal of Cosmetic Dermatology · 5
Do interleukin-17 and interleukin-23 inhibitors alter the coagulation parameters in psoriasis patients?: A retrospective study
2024 · Simge Ünal, Tuğcan Yüksek, et al. · Archives of Dermatological Research · 3
The relationship between direct immunofluorescence findings and clinical and laboratory parameters in patients with cutaneous small vessel vasculitis
2020 · Duygu Gulseren, Ece Erbağcı, et al. · Turkish Journal of Dermatology · 3
Predictive Factors of Early Super-Response to Biologic Agents in Psoriasis: Insights from Real-World Evidence
2026 · Sema Koç Yıldırım, Saadet Ayyıldız, et al. · Clinical Cosmetic and Investigational Dermatology · 2
PDF
Serum C‐Reactive Protein as a Potential Indicator for Screening Fecal Calprotectin in Patients With Moderate‐to‐Severe Hidradenitis Suppurativa: A Cross‐Sectional Cohort Study
2025 · Neslihan Demirel Öğüt, Rahşan Ilıkçı Sağkan, et al. · International Journal of Dermatology · 2
PDF
Merkel cell number and distribution, and CD200 expression in patients with lichen planopilaris and discoid lupus erythematosus
2022 · Ece Erbağcı, Ayşen Karaduman, et al. · Journal of Cutaneous Pathology · 2
Evaluation of the Relationship Between Clinical Features of Acrochordons and Metabolic Syndrome Components: Prospective Cross-Sectional Study
2026 · Sema KOÇ YILDIRIM, Ece ERBAĞCI, et al. · Turkiye Klinikleri Journal of Dermatology · 1
PDF
Vaskülitler
2024 · Ece Erbağcı, Ömer Kutlu · 1
The frequency and characteristics of itching in severe COVID‐19 patients: first report
2021 · Ömer Kutlu, Neslihan Demirel Öğüt, et al. · International Journal of Dermatology · 1
PDF
Evaluation of Factors Associated with a History of Skin Cancer in Patients with Actinic Keratosis: AKASI as a Clinical Tool for Risk Stratification
2026 · Ece Erbağcı, Sema Koç Yıldırım, et al. · Turkish Journal of Dermatology
PDF
Hepatitis B Reactivation in Biologic‐Treated Moderate‐to‐Severe Psoriasis: A Real‐World Cohort Study With 534 Patient‐Years of Follow‐Up
2026 · Neslihan Demirel Öğüt, Muhammed Numan Sarıdaş, et al. · Dermatologic Therapy
Assessing the Role of Baseline Creatine Kinase Measurement Before Initiating Oral Isotretinoin in Acne Vulgaris Patients: Insights From a Retrospective Cohort of 1256 Individuals
2026 · Neslihan Demirel Öğüt, Saadet Miray Ayyıldız, et al. · Dermatologic Therapy
Diagnosis and Treatment of Pyoderma Gangrenosum
2025 · Erbağcı, Ece · Ege Tıp Bilimleri Dergisi
Simultaneous HBV Reactivation and Hair Discoloration Under Secukinumab Treatment.
2025 · Ece Erbağcı · PubMed
PDF
Works count: 29
Citation count: 142
H-index: 7
I10-index: 5
Year
Topic
Type